ENGNW NASDAQ
enGene Holdings Inc. Warrants
1W: -14.2%
1M: -36.1%
3M: +11.4%
YTD: -91.2%
1Y: -71.6%
$0.23
+0.00 (+0.00%)
Weekly Expected Move ±65.2%
$-0
$0
$0
$0
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.8M
52W Range0.21-2.1
Volume800
Avg Volume13,235
Beta-0.28
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORonald H. W. Cooper
Employees82
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
4868 Rue Levy
Montreal, QC H4R 2P1
CA
Montreal, QC H4R 2P1
CA
514 332 4888
About enGene Holdings Inc. Warrants
EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CHEUNG ANTHONY TZEYE | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Giguere Lee | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Nichols Alexander Ju | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Daws D. Ryan | A-Award | 220,000 | $9.53 | 2026-01-30 |
| Cooper Ronald Harold | A-Award | 801,000 | $9.53 | 2026-01-30 |